/
Oncology
Hematologic Cancer
17
Pipeline Programs↗
14
Active Trials↗
20
Companies Involved↗
Hematologic Cancer is an emerging landscape with 17 programs across 20 companies. The most active players are Indapta Therapeutics, INC., AbbVie.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 15
Phase 28
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
69%
Small molecule
9 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 76% of 17 pipeline programs.
Analysis
Trial Status
68
clinical trials
Completed40 · 59%
Terminated11 · 16%
Recruiting6 · 9%
Not yet recruiting5 · 7%
Active, not recruiting3 · 4%
Withdrawn2 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
68 trials
IIT2021-11-PAQUETTE-OmitMMF: Fludarabine and Total Body Irradiation 800 cGy or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
Active, not recruiting·—·Phase 2·NCT05256537·60 enrolled
Prospective Exploratory Study of Standard-Dose Ceftazidime-Avibactam PK/PD Target Attainment, Clinical Outcomes, and Induced Resistance in Patients With Hematological Malignancies
Not yet recruiting·—·N/A·NCT07703644·60 enrolled
Take5Care+: A Self-management Educational Intervention to Support the Haematology Patients' Journey Following a Neoplastic Diagnosis.
Not yet recruiting·—·Preclinical·NCT07674212·20 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)